Tactical Therapeutics (TTI) is a clinical-stage company that develops Carboxyamidotriazole Orotate (CTO) (Pravitinib), a therapeutic for the orphan indication glioblastoma (GBM) and other refractory targets. GBM (grade IV astrocytoma) is a brain tumor that is highly resistant to common DNA-modifying agents, exhibiting aggressive spatial and molecular heterogeneity with multiple gene amplification signaling pathways.